Is SHLP2 legal in Australia?

A mitochondrial-derived peptide with an identified receptor, a mouse obesity result and a human genetic association with protection against Parkinson's disease. It has never been administered to a person, and no trial is registered.

In 2016 a search of the same stretch of mitochondrial 16S ribosomal RNA that encodes humanin turned up six more short open reading frames. Those became SHLP1 through SHLP6, the small humanin-like peptides.

Mechanism: Encoded in the mitochondrial genome, in the 16S rRNA region, and released to act as a signalling peptide. The identified receptor is CXCR7, an atypical chemokine receptor.

Regulatory history: Not approved, not in development as a drug in any public filing, and with no investigational new drug programme located. It is an endogenous peptide that people can measure in plasma, not a product.

Registers or lists therapeutic goods on the ARTG and schedules substances in the Poisons Standard. Many peptides are Schedule 4 (prescription only), so possession without a prescription and personal importation are restricted even when no product is registered.

The classification above is the The Longevity Archive reading of Therapeutic Goods Administration listings for SHLP2 at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.